Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19176107 | 0.90 | CHRM5 (0.45) | NR1H2CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL9350724 | 0.89 | GPR119 (0.47) | NR1H2CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL3085985 | 0.87 | CHRM5 (0.41) | NR1H2CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL5941814 | 0.84 | CHRM5 (0.45) | NR1H2CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL1750511 | 0.84 | ESR2 (0.53) | NR1H2CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL5941865 | 0.84 | CHRM5 (0.43) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL5272921 | 0.84 | CHRM5 (0.39) | NR1H2CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL19168831 | 0.83 | CHRM5 (0.46) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3197517 | 0.83 | SLC6A3 (0.54) | NR1H2CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL951478 | 0.83 | NR1H2 (0.47) | NR1H2CHRM5CHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620403-B1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-28 | — | — | EP | disclosed |
| CN-1972912-A | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-05-30 | — | — | CN | disclosed |
| US-20060235056-A1 | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-10-19 | — | — | US | disclosed |
| EP-1620403-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004096769-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | REN, ACE, ACE2 | NR1H2 3093/4885CYP4A11 355/4885CHRM5 1155/4885 |
| US-20060235056-A1 | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | REN, ACE, ACE2 | NR1H2 3453/4885CYP4A11 83/4885CHRM5 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.